Skip to main content

Wrinkles

2
Pipeline Programs
9
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Botulinum Toxin Type-APhase 41 trial
Active Trials
NCT01297634Completed64Est. Nov 2011
Galderma
GaldermaTX - Dallas
1 program
1
Botulinum Toxin Type A - AzzalurePhase 21 trial
Active Trials
NCT01014871Completed30Est. May 2010
Anika Therapeutics
Anika TherapeuticsMA - Bedford
2 programs
ElevessN/A1 trial
Hyaluronic Acid Dermal FillerN/A
Active Trials
NCT01147172Completed100Est. Aug 2010
Lumenis
LumenisAustralia - Chatswood
1 program
M22 ResurFX moduleN/A1 trial
Active Trials
NCT01796626Completed36Est. Jul 2014
ReVision Therapeutics
ReVision TherapeuticsNJ - Ridgewood
1 program
Onabotulinumtoxin AN/A1 trial
Active Trials
NCT05089851Completed29Est. Jun 2021
Medical 21
Medical 21MN - Minneapolis
1 program
PDO sutureN/A1 trial
Active Trials
NCT07068061Not Yet Recruiting50Est. Jul 2026
Century Therapeutics
Century TherapeuticsPHILADELPHIA, PA
1 program
PDO sutureN/A
Deka Biosciences
Deka BiosciencesMD - Germantown
1 program
TriActive+ RFN/A1 trial
Active Trials
NCT01460927CompletedEst. Apr 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieBotulinum Toxin Type-A
GaldermaBotulinum Toxin Type A - Azzalure
Medical 21PDO suture
ReVision TherapeuticsOnabotulinumtoxin A
LumenisM22 ResurFX module
Deka BiosciencesTriActive+ RF
Anika TherapeuticsElevess

Clinical Trials (7)

Total enrollment: 309 patients across 7 trials

NCT01297634AbbVieBotulinum Toxin Type-A

Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle

Start: May 2011Est. completion: Nov 201164 patients
Phase 4Completed
NCT01014871GaldermaBotulinum Toxin Type A - Azzalure

Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles

Start: Jul 2009Est. completion: May 201030 patients
Phase 2Completed
NCT07068061Medical 21PDO suture

PER-SAF_PDOS (Performance and Safety of Polydioxanone Suture)

Start: Sep 2025Est. completion: Jul 202650 patients
N/ANot Yet Recruiting
NCT05089851ReVision TherapeuticsOnabotulinumtoxin A

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

Start: Aug 2020Est. completion: Jun 202129 patients
N/ACompleted
NCT01796626LumenisM22 ResurFX module

Clinical Evaluation of M22 ResurFX 1565nm Module

Start: Dec 2012Est. completion: Jul 201436 patients
N/ACompleted
NCT01460927Deka BiosciencesTriActive+ RF

TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides

Start: Oct 2011Est. completion: Apr 2012
N/ACompleted
NCT01147172Anika TherapeuticsElevess

Safety Study of Cosmetic Tissue Augmentation in People of Color

Start: Mar 2009Est. completion: Aug 2010100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.